Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Aki, Semiha; * | Gulbaba, R. Gunayb | Eskiyurt, Nurtena
Affiliations: [a] Istanbul University, Medical School, Department of Physical Medicine and Rehabilitation, Istanbul, Turkey | [b] RIA Laboratory, Istanbul, Turkey
Correspondence: [*] Address for correspondence: Ass. Prof. Semih Aki, Istanbul Tip Fakultesi, Fiziksel Tip ve Rehabilitasyon Anabilim Dali, Capa, Istanbul, Turkey. Tel.: +90 2163868087; Fax: +90 2126358522; +90 2125318319; E-mail: semihaki@yahoo.com
Abstract: The aim of this randomized, controlled study was to evalaute effects of 12 months alendronate therapy on bone mineral density (BMD) and markers of bone formation and resorption in women with postmenopausal osteoporosis. Study enrolled women with BMD at least 2 SD below adult, premenopausal BMD mean. Patients to be treated were randomized into two groups. Patients in the control group received 500 mg elemental calcium tablet daily and treatment group received 10 mg/day alendronate and 500 mg elemental calcium tablet for twelve months. Pretreatment characteristics of patients in both groups were similar. A significant increase in BMD of the treatment group patients compared to control group was observed at 12 months (p < 0.001). Markers of bone formation and resorption in the treatment group reduced significantly at 6 and 12 months of therapy compared to control group (p < 0.001). In conclusion, we found that 12 months alendronate therapy (10 mg/day) significantly increased BMD in all sites of measurement compared to control group and also significantly reduced markers of bone formation and resorption at all time points (at 6 and 12 months) in postmenopausal women with osteoporosis compared to control group. It is fact that bone density clearly improved by alendronate therapy and the biochemical markers were shown as valid tools for monitoring and prediction of treatment effect of alendronate therapy.
Keywords: postmenopausal osteoporosis, alendronate, bone mineral density, markers of bone formation and resorption
DOI: 10.3233/BMR-2004-17106
Journal: Journal of Back and Musculoskeletal Rehabilitation, vol. 17, no. 1, pp. 27-31, 2004
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl